Strategies for development of dengue virus inhibitors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ackermann, 2001, De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase, J. Biol. Chem., 276, 39926, 10.1074/jbc.M104248200
Alen, 2009, Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection, Virology, 387, 67, 10.1016/j.virol.2009.01.043
Aleshin, 2007, Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold, Protein Sci., 16, 795, 10.1110/ps.072753207
Antonysamy, 2008, Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors, Bioorg. Med. Chem. Lett., 18, 2990, 10.1016/j.bmcl.2008.03.056
Atrasheuskaya, 2003, Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection, FEMS Immunol. Med. Microbiol., 35, 33, 10.1111/j.1574-695X.2003.tb00646.x
Barbas, 1997, Immune versus natural selection: antibody aldolases with enzymic rates but broader scope, Science, 278, 2085, 10.1126/science.278.5346.2085
Bazan, 1989, Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses, Virology, 171, 637, 10.1016/0042-6822(89)90639-9
Beaulieu, 2006, Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds, Bioorg. Med. Chem. Lett., 16, 4987, 10.1016/j.bmcl.2006.07.074
Bente, 2005, Dengue fever in humanized NOD/SCID mice, J. Virol., 79, 13797, 10.1128/JVI.79.21.13797-13799.2005
Berkowitz, 1985, Use of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus, Antimicrob. Agents Chemother., 28, 207, 10.1128/AAC.28.2.207
Betz, 2002, Potent in vivo antiviral activity of the herpes simplex virus primase–helicase inhibitor BAY 57-1293, Antimicrob. Agents Chemother., 46, 1766, 10.1128/AAC.46.6.1766-1772.2002
Biswas, 2007, The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1, Antiviral Res., 75, 30, 10.1016/j.antiviral.2006.11.006
Boguszewska-Chachulska, 2004, Direct fluorometric measurement of hepatitis C virus helicase activity, FEBS Lett., 567, 253, 10.1016/j.febslet.2004.04.072
Carroll, 2009, Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees, Antimicrob. Agents Chemother., 53, 926, 10.1128/AAC.01032-08
Carroll, 2006, Nucleoside analog inhibitors of hepatitis C virus replication, Infect. Disord. Drug Targets, 6, 17, 10.2174/187152606776056698
Chambers, 1991, Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites, J. Virol., 65, 6042, 10.1128/JVI.65.11.6042-6050.1991
Chambers, 1990, Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein, Proc. Nat. Acad. Sci. U.S.A., 87, 8898, 10.1073/pnas.87.22.8898
Chen, 2008, CLEC5A is critical for dengue-virus-induced lethal disease, Nature, 453, 672, 10.1038/nature07013
Chu, 2005, Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein, J. Gen. Virol., 86, 405, 10.1099/vir.0.80411-0
Chu, 2007, c-Src protein kinase inhibitors block assembly and maturation of dengue virus, Proc. Natl. Acad. Sci. U.S.A., 104, 3520, 10.1073/pnas.0611681104
Cleaves, 1979, Methylation status of intracellular Dengue type 2 40S RNA, Virology, 96, 159, 10.1016/0042-6822(79)90181-8
Cordin, 2006, The DEAD-box protein family of RNA helicases, Gene, 367, 17, 10.1016/j.gene.2005.10.019
Cote, 2002, Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients, N. Engl. J. Med., 346, 811, 10.1056/NEJMoa012035
Courageot, 2000, Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum, J. Virol., 74, 564, 10.1128/JVI.74.1.564-572.2000
Crill, 2001, Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells, J. Virol., 75, 7769, 10.1128/JVI.75.16.7769-7773.2001
Dong, 2007, Distinct RNA elements confer specificity to flavivirus RNA cap methylation events, J. Virol., 81, 4412, 10.1128/JVI.02455-06
Dong, 2008, Flavivirus methyltransferase: a novel antiviral target, Antiviral Res., 80, 1, 10.1016/j.antiviral.2008.05.003
Earnshaw, 1999, Time-resolved fluorescence energy transfer DNA helicase assays for high throughput screening, J. Biomol. Screen., 4, 239, 10.1177/108705719900400505
Egloff, 2002, An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization, EMBO J., 21, 2757, 10.1093/emboj/21.11.2757
Egloff, 2007, Structural and functional analysis of methylation and 5′-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5, J. Mol. Biol., 372, 723, 10.1016/j.jmb.2007.07.005
Ekonomiuk, 2009, Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking, PLoS Negl. Trop. Dis., 3, e356, 10.1371/journal.pntd.0000356
Elshuber, 2003, Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus, J. Gen. Virol., 84, 183, 10.1099/vir.0.18723-0
Erbel, 2006, Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus, Nat. Struct. Mol. Biol., 13, 372, 10.1038/nsmb1073
Falgout, 1993, Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B–NS3 protease activity, J. Virol., 67, 2034, 10.1128/JVI.67.4.2034-2042.1993
Fenouillet, 1991, Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein, J. Gen. Virol., 72, 1919, 10.1099/0022-1317-72-8-1919
Furuichi, 2000, Viral and cellular mRNA capping: past and prospects, Adv. Virus Res., 55, 135, 10.1016/S0065-3527(00)55003-9
Goncalvez, 2007, Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention, Proc. Natl. Acad. Sci. U.S.A., 104, 9422, 10.1073/pnas.0703498104
Gouvea, 2007, Substrate specificity of recombinant dengue 2 virus NS2B–NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates, Arch. Biochem. Biophys., 457, 187, 10.1016/j.abb.2006.11.005
Green, 2008, Cell-based assays to identify inhibitors of viral disease, Expert Opin. Drug Discov., 3, 671, 10.1517/17460441.3.6.671
Gromowski, 2008, Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus, J. Virol., 82, 8828, 10.1128/JVI.00606-08
Gu, 2007, Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus, Antivir. Chem. Chemother., 18, 49, 10.1177/095632020701800105
Gubler, 2007, Flaviviruses, vol. 1, 1153
Gubler, 1981, Epidemic dengue 3 in central Java, associated with low viremia in man, Am. J. Trop. Med. Hyg., 30, 1094, 10.4269/ajtmh.1981.30.1094
Guo, 2005, West nile virus inhibits the signal transduction pathway of alpha interferon, J. Virol., 79, 1343, 10.1128/JVI.79.3.1343-1350.2005
Halstead, 2003, Neutralization and antibody-dependent enhancement of dengue viruses, Adv. Virus Res., 60, 421, 10.1016/S0065-3527(03)60011-4
Han, 1998, 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter, Pharm. Res., 15, 1154, 10.1023/A:1011919319810
Harrison, 2005, Mechanism of membrane fusion by viral envelope proteins, Adv. Virus Res., 64, 231, 10.1016/S0065-3527(05)64007-9
Hesterkamp, 2008, Fragment-based activity space: smaller is better, Curr. Opin. Chem. Biol., 12, 260, 10.1016/j.cbpa.2008.02.005
Hezareh, 2001, Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1, J. Virol., 75, 12161, 10.1128/JVI.75.24.12161-12168.2001
Hirsch, 2005, The Src family kinase c-Yes is required for maturation of West Nile virus particles, J. Virol., 79, 11943, 10.1128/JVI.79.18.11943-11951.2005
Hrobowski, 2005, Peptide inhibitors of dengue virus and West Nile virus infectivity, Virol. J., 2, 49, 10.1186/1743-422X-2-49
Iempridee, 2008, A comparative biochemical analysis of the NS2B(H)–NS3pro protease complex from four dengue virus serotypes, Biochim. Biophys. Acta, 1780, 989, 10.1016/j.bbagen.2008.03.018
Jhoti, 2007, Fragment-based screening using X-ray crystallography and NMR spectroscopy, Curr. Opin. Chem. Biol., 11, 485, 10.1016/j.cbpa.2007.07.010
Jindadamrongwech, 2004, Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2, Arch. Virol., 149, 915, 10.1007/s00705-003-0263-x
Kandil, 2009, Discovery of a novel HCV helicase inhibitor by a de novo drug design approach, Bioorg. Med. Chem. Lett., 19, 2935, 10.1016/j.bmcl.2009.04.074
Khromykh, 1998, Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans, J. Virol., 72, 5967, 10.1128/JVI.72.7.5967-5977.1998
Kroschewski, 2008, Mutagenesis of the dengue virus type 2 NS5 methyltransferase domain, J. Biol. Chem., 283, 19410, 10.1074/jbc.M800613200
Kummerer, 2002, Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles, J. Virol., 76, 4773, 10.1128/JVI.76.10.4773-4784.2002
Kuritzkes, 2009, HIV-1 entry inhibitors: an overview, Curr. Opin. HIV AIDS, 4, 82, 10.1097/COH.0b013e328322402e
Kyono, 1998, Detection of hepatitis C virus helicase activity using the scintillation proximity assay system, Anal. Biochem., 257, 120, 10.1006/abio.1998.2560
Le Pogam, 2008, Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients, J. Antimicrob. Chemother., 61, 1205, 10.1093/jac/dkn085
Leary, 2002, Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines, Antimicrob. Agents Chemother., 46, 762, 10.1128/AAC.46.3.762-768.2002
Lee, 2008, Cholesterol effectively blocks entry of flavivirus, J. Virol., 82, 6470, 10.1128/JVI.00117-08
Leung, 2001, Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors, J. Biol. Chem., 276, 45762, 10.1074/jbc.M107360200
Li, 2005, Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries, J. Biol. Chem., 280, 28766, 10.1074/jbc.M500588200
Liao, 2005, Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion, J. Cell Biol., 171, 111, 10.1083/jcb.200507075
Libraty, 2002, High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever, J. Infect. Dis., 186, 1165, 10.1086/343813
Lindenbach, 1997, Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication, J. Virol., 71, 9608, 10.1128/JVI.71.12.9608-9617.1997
Lisova, 2007, Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus, J. Gen. Virol., 88, 2387, 10.1099/vir.0.83028-0
Liu, 2005, Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins, J. Virol., 79, 1934, 10.1128/JVI.79.3.1934-1942.2005
Liu, 2003, Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication, J. Virol., 77, 7804, 10.1128/JVI.77.14.7804-7813.2003
Lok, 2008, Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins, Nat. Struct. Mol. Biol., 15, 312, 10.1038/nsmb.1382
Lubeck, 1980, Antigenic variants of influenza viruses: marked differences in the frequencies of variants selected with different monoclonal antibodies, Virology, 102, 458, 10.1016/0042-6822(80)90114-2
Luo, 2007, Crystal structure of the NS3 protease–helicase from Dengue virus, J. Virol.
Luo, 2008, Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein, EMBO J., 27, 3209, 10.1038/emboj.2008.232
Luplertlop, 2006, Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction, EMBO Rep., 7, 1176, 10.1038/sj.embor.7400814
Ma, 2004, Solution structure of dengue virus capsid protein reveals another fold, Proc. Natl. Acad. Sci. U.S.A., 101, 3414, 10.1073/pnas.0305892101
Maga, 2005, Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663, Biochemistry, 44, 9637, 10.1021/bi047437u
Malet, 2007, Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5, J. Biol. Chem., 282, 10678, 10.1074/jbc.M607273200
Malet, 2008, The flavivirus polymerase as a target for drug discovery, Antiviral Res., 80, 23, 10.1016/j.antiviral.2008.06.007
Mancini, 2007, Structure of the Murray Valley encephalitis virus RNA helicase at 1.9 Angstrom resolution, Protein Sci., 16, 2294, 10.1110/ps.072843107
Marcon, 2008, A dual-purpose synthetic colloidal platform for protease mapping: substrate profiling for Dengue and West Nile virus proteases, Anal. Biochem., 376, 151, 10.1016/j.ab.2008.01.034
Markland, 2000, Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon, Antimicrob. Agent. Chemother., 44, 859, 10.1128/AAC.44.4.859-866.2000
Martins, 2008, The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection, Curr. Med. Chem., 15, 1083, 10.2174/092986708784221467
McCown, 2003, The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses, Virology, 313, 514, 10.1016/S0042-6822(03)00341-6
Menéndez-Arias, L., 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res., doi:10.1016/j.antiviral.2009.07.006.
Migliaccio, 2003, Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro, J. Biol. Chem., 278, 49164, 10.1074/jbc.M305041200
Miller, 2008, The mannose receptor mediates dengue virus infection of macrophages, PLoS Pathog., 4, e17, 10.1371/journal.ppat.0040017
Miller, 2007, The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner, J. Biol. Chem., 282, 8873, 10.1074/jbc.M609919200
Miller, 2006, Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B, J. Biol. Chem., 281, 8854, 10.1074/jbc.M512697200
Modis, 2003, A ligand-binding pocket in the dengue virus envelope glycoprotein, Proc. Natl. Acad. Sci. U.S.A., 100, 6986, 10.1073/pnas.0832193100
Modis, 2004, Structure of the dengue virus envelope protein after membrane fusion, Nature, 427, 313, 10.1038/nature02165
Mooij, 2006, Automated protein–ligand crystallography for structure-based drug design, ChemMedChem, 1, 827, 10.1002/cmdc.200600074
Mota, 2009, Humanized mice show clinical signs of dengue fever according to infecting virus genotype, J. Virol., 83, 8638, 10.1128/JVI.00581-09
Moyle, 2000, Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?, Drug Saf., 23, 467, 10.2165/00002018-200023060-00001
Mueller, 2008, Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen, Antimicrob. Agents Chemother., 52, 3385, 10.1128/AAC.01508-07
Mueller, 2007, Characterization of the West Nile virus protease substrate specificity and inhibitors, Int. J. Biochem. Cell Biol., 39, 606, 10.1016/j.biocel.2006.10.025
Munoz-Jordan, 2005, Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses, J. Virol., 79, 8004, 10.1128/JVI.79.13.8004-8013.2005
Munoz-Jordan, 2003, Inhibition of interferon signaling by dengue virus, Proc. Natl. Acad. Sci. U.S.A., 100, 14333, 10.1073/pnas.2335168100
Navarro-Sanchez, 2003, Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses, EMBO Rep., 4, 723, 10.1038/sj.embor.embor866
Ng, 2007, Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing, Antiviral Res., 76, 222, 10.1016/j.antiviral.2007.06.007
Niyomrattanakit, 2006, Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides, Biochem. J., 397, 203, 10.1042/BJ20051767
Oliphant, 2005, Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus, Nat. Med., 11, 522, 10.1038/nm1240
Pang, 2001, Development of Dengue virus type 2 replicons capable of prolonged expression in host cells, BMC Microbiol., 1, 18, 10.1186/1471-2180-1-18
Pastor-Anglada, 2005, Cell entry and export of nucleoside analogues, Virus Res., 107, 151, 10.1016/j.virusres.2004.11.005
Pauwels, 2007, Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors, J. Virol., 81, 6909, 10.1128/JVI.01543-06
Pellerin, 2002, Internal initiation sites of de novo RNA synthesis within the hepatitis C virus polypyrimidine tract, Biochem. Biophys. Res. Commun., 295, 682, 10.1016/S0006-291X(02)00743-X
Perera, 2008, Closing the door on flaviviruses: entry as a target for antiviral drug design, Antiviral Res., 80, 11, 10.1016/j.antiviral.2008.05.004
Perrone, 2007, First example of phosphoramidate approach applied to a 4′-substituted purine nucleoside (4′-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus, J. Med. Chem., 50, 5463, 10.1021/jm070362i
Perrone, 2007, Application of the phosphoramidate ProTide approach to 4′-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside, J. Med. Chem., 50, 1840, 10.1021/jm0613370
Poh, M.K., Yip, A., Zhang, S., Priestle, J.P., Ma, N.L., Smit, J.M., Wilschut, J., Shi, P.-Y., Wenk, M.R., Schul, W., 2009. A small molecule fusion inhibitor of dengue virus. Antiviral Res.
Preugschat, 1990, In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3, J. Virol., 64, 4364, 10.1128/JVI.64.9.4364-4374.1990
Prusis, 2008, Proteochemometrics analysis of substrate interactions with dengue virus NS3 proteases, Bioorg. Med. Chem., 16, 9369, 10.1016/j.bmc.2008.08.081
Puig-Basagoiti, 2005, High-throughput assays using luciferase-expressing replicon, virus-like particle, and full-length virus for West Nile virus drug discovery, Antimicrob. Agent. Chemother., 49, 4980, 10.1128/AAC.49.12.4980-4988.2005
Puig-Basagoiti, 2006, Triaryl pyrazoline compound inhibits flavivirus RNA replication, Antimicrob. Agents Chemother., 50, 1320, 10.1128/AAC.50.4.1320-1329.2006
Pyle, 2008, Translocation and unwinding mechanisms of RNA and DNA helicases, Annu. Rev. Biophys., 37, 317, 10.1146/annurev.biophys.37.032807.125908
Ray, 2006, West nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5, J. Virol., 80, 8362, 10.1128/JVI.00814-06
Rey, 1995, The envelope glycoprotein from tick-borne encephalitis virus at 2A resolution, Nature, 375, 291, 10.1038/375291a0
Rothwell, 2009, Cholesterol biosynthesis modulation regulates dengue viral replication, Virology, 389, 8, 10.1016/j.virol.2009.03.025
Shiryaev, 2006, Cleavage targets and the d-arginine-based inhibitors of the West Nile virus NS3 processing proteinase, Biochem. J., 393, 503, 10.1042/BJ20051374
Shiryaev, 2009, NS4A regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-structural protein NS4A from West Nile virus, J. Gen. Virol., 90, 2081, 10.1099/vir.0.012864-0
Shresta, 2006, Murine model for dengue virus-induced lethal disease with increased vascular permeability, J. Virol., 80, 10208, 10.1128/JVI.00062-06
Sivaraja, 1998, High-throughput screening assay for helicase enzymes, Anal. Biochem., 265, 22, 10.1006/abio.1998.2875
Soriano, 2008, Emerging drugs for hepatitis C, Expert Opin. Emerg. Drugs, 13, 1, 10.1517/14728214.13.1.1
Souza, 2009, Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection, Proc. Natl. Acad. Sci. U.S.A., 106, 14138, 10.1073/pnas.0906467106
Sriburi, 2001, Construction of infectious dengue 2 virus cDNA clones using high copy number plasmid, J. Virol. Methods, 92, 71, 10.1016/S0166-0934(00)00277-9
Srikiatkhachorn, 2007, Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever, J. Virol., 81, 1592, 10.1128/JVI.01642-06
Stadler, 1997, Proteolytic activation of tick-borne encephalitis virus by furin, J. Virol., 71, 8475, 10.1128/JVI.71.11.8475-8481.1997
Talavera, 2004, IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers, J. Gen. Virol., 85, 1801, 10.1099/vir.0.19652-0
Tan, 1996, Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity, Virology, 216, 317, 10.1006/viro.1996.0067
Tassaneetrithep, 2003, DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells, J. Exp. Med., 197, 823, 10.1084/jem.20021840
Tatarowicz, 1991, In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus, J. Virol. Methods, 35, 207, 10.1016/0166-0934(91)90136-N
Thepparit, 2004, Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor, J. Virol., 78, 12647, 10.1128/JVI.78.22.12647-12656.2004
Valle, 1998, Mutagenesis of the NS3 protease of dengue virus type 2, J. Virol., 72, 624, 10.1128/JVI.72.1.624-632.1998
van der Schaar, 2008, Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells, PLoS Pathog., 4, e1000244, 10.1371/journal.ppat.1000244
von Moeller, 2009, The mRNA export protein DBP5 binds RNA and the cytoplasmic nucleoporin NUP214 in a mutually exclusive manner, Nat. Struct. Mol. Biol., 16, 247, 10.1038/nsmb.1561
Wang, 2009, A small-molecule dengue virus entry inhibitor, Antimicrob. Agents Chemother., 53, 1823, 10.1128/AAC.01148-08
Wengler, 1981, Terminal sequences of the genome and replicative-form RNA of the flavivirus West Nile virus: absence of poly(A) and possible role in RNA replication, Virology, 113, 544, 10.1016/0042-6822(81)90182-3
Wengler, 1991, The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase, Virology, 184, 707, 10.1016/0042-6822(91)90440-M
Wengler, 1993, The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity, Virology, 197, 265, 10.1006/viro.1993.1587
Whitby, 2005, Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo, J. Virol., 79, 8698, 10.1128/JVI.79.14.8698-8706.2005
Wu, 2005, Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing, J. Virol., 79, 10268, 10.1128/JVI.79.16.10268-10277.2005
Wu, 2005, Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase, Mini Rev. Med. Chem., 5, 1103, 10.2174/138955705774933310
Wu, 2002, Antiviral effects of an iminosugar derivative on flavivirus infections, J. Virol., 76, 3596, 10.1128/JVI.76.8.3596-3604.2002
Xu, 2005, Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4A, J. Virol., 79, 10278, 10.1128/JVI.79.16.10278-10288.2005
Yamashita, 2008, Crystal structure of the catalytic domain of Japanese encephalitis virus NS3 helicase/nucleoside triphosphatase at a resolution of 1.8A, Virology, 373, 426, 10.1016/j.virol.2007.12.018
Yap, 2007, Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution, J. Virol., 81, 4753, 10.1128/JVI.02283-06
Yedavalli, 2004, Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function, Cell, 119, 381, 10.1016/j.cell.2004.09.029
Yedavalli, 2008, Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication, J. Med. Chem., 51, 5043, 10.1021/jm800332m
Yin, 2009, An adenosine nucleoside inhibitor of dengue virus, Proc. Natl. Acad. Sci. U.S.A., 106, 20435, 10.1073/pnas.0907010106
Yusof, 2000, Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro, J. Biol. Chem., 275, 9963, 10.1074/jbc.275.14.9963
Zhang, 2009, Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus, J. Infect. Dis., 200, 202, 10.1086/599794
Zhou, 2007, Structure and function of flavivirus NS5 methyltransferase, J. Virol., 81, 3891, 10.1128/JVI.02704-06